Evidence map›Paper›PMID 41214690›Full record

ArticleJournal of nanobiotechnology2025

Targeting bone marrow adipocyte-driven fatty acid metabolism to overcome drug resistance in lung cancer bone metastasis.

Jian Dong, Huaze Ding, Shuoer Wang, Shengzhe Ruan, Jianxin Ye, Peng Hu, Tong Meng, Wangjun Yan, Lei Zhou, Changping Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jian Dong *Department of Orthopedics, Shanghai General Hospital of Nanjing Medical University, Shanghai, 200080, China.
Huaze Ding *Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Shuoer Wang *Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Shengzhe Ruan *Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Jianxin YeDepartment of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Peng HuDepartment of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Tong MengDepartment of Orthopedics, Shanghai General Hospital of Nanjing Medical University, Shanghai, 200080, China.
Wangjun YanDepartment of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Lei ZhouDepartment of Orthopedics, Shanghai General Hospital of Nanjing Medical University, Shanghai, 200080, China. zl8160@163.com.
Changping WangDepartment of Orthopedics, Shanghai General Hospital of Nanjing Medical University, Shanghai, 200080, China. wangchp@sjtu.edu.cn.
Dianwen SongDepartment of Orthopedics, Shanghai General Hospital of Nanjing Medical University, Shanghai, 200080, China. songdianwen@msn.com.

Funding

National Natural Science Foundation of China 82073207National Natural Science Foundation of China 82373178
6 · The paper itself

Abstract

Lung cancer remains a leading cause of cancer-related mortality worldwide, with bone metastasis presenting a significant challenge due to its association with severe skeletal complications and therapy resistance. This study investigates the role of bone marrow adipocytes (BMAs) in modulating fatty acid metabolism within the bone metastatic niche of lung cancer. Utilizing single-cell sequencing and in vitro co-culture models, we identified critical interactions between BMAs and metastatic lung cancer cells that enhance fatty acid metabolism, promoting tumor survival and drug resistance. To target this metabolic axis, we screened a library of fatty acid synthesis inhibitors, and developed a nanoparticle system encapsulating kaempferol, and cisplatin, surface-modified with poly-aspartic acid for efficient bone targeting. The nanoparticles release their therapeutic payload in the acidic tumor microenvironment, disrupting fatty acid metabolism and overcoming chemoresistance. Our findings highlight the metabolic reprogramming driven by BMAs in bone metastasis and propose a novel therapeutic strategy to improve outcomes for patients with metastatic lung cancer.

Indexed as

AdipocytesBone NeoplasmsDrug Resistance, NeoplasmFatty AcidsLung NeoplasmsAnimalsAntineoplastic AgentsBone MarrowCell Line, TumorCisplatinCoculture TechniquesHumansMiceNanoparticlesTumor MicroenvironmentAntineoplastic AgentsCisplatinFatty AcidsBone marrow adipocytesCisplatin resistanceFatty acid metabolismLung cancer bone metastasisNanomedicines

Identifiers

PMID41214690
PMCPMC12604269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.